Impact Biomedical IBO Institutional Ownership

Updated Oct 5, 2026

Impact Biomedical Inc. (NYSE:IBO) was reported as a holding by 22 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Together they owned 3.56% of the outstanding stock in Q2 2026, up from 3.45% a quarter earlier.
• Total shares held in Impact Biomedical rose 3.01% from Q1 2026, while the number of holders rose 15.79% from Q2 2025.
• Of the 22 holders of IBO in Q2 2026, 7 added to their positions, 5 reduced their stakes and 10 left their positions unchanged.
• In total, institutional investors held 3.83Mn shares of Impact Biomedical at the end of Q2 2026, up 112K from the prior quarter and up 3.36Mn from a year earlier.
• Geode Capital Management, LLC led 13F holders of IBO with 1.19Mn shares as of June 30, 2026, or 1.10% of shares outstanding.
• Holders that added the most shares of Impact Biomedical in Q2 2026 were Vanguard Capital Management LLC (+100.52K shares), Vanguard Fiduciary Trust Co (+4.23K shares), Morgan Stanley (+11 shares) and FMR LLC (+2 shares).
• Among holders that kept a stake in Impact Biomedical, the biggest sellers in Q2 2026 were UBS Group AG (-30.02K shares), Two Sigma Investments, LP (-20.24K shares), Northern Trust Corp (-8.47K shares), Geode Capital Management, LLC (-7.76K shares) and Citigroup Inc (-352 shares).
• Business Quant data shows the 10 biggest positions in Impact Biomedical as of Q2 2026 were held by Geode Capital Management, LLC (1.19Mn shares), Vanguard Capital Management LLC (808.69K shares), State Street Corp (607.9K shares), Vanguard Fiduciary Trust Co (589.43K shares), BlackRock, Inc. (259.95K shares), Northern Trust Corp (235.47K shares), Citadel Advisors LLC (49.57K shares), Vanguard Global Advisers, LLC (32.2K shares), Jane Street Group, LLC (24.53K shares) and Two Sigma Investments, LP (17.19K shares).